Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

Chronic obstructive pulmonary disease (COPD) affects 25 million people in the U.S. and is the fifth leading cause of death ...

Short-course fluoroquinolone treatment is as effective as the conventional 7-day course for acute exacerbations of chronic ...

Emphysema is a slow killer. Severe emphysema even alienates family members as the patients relegate themselves to the length of their oxygen tubing and suffer through an acquired mutism from ...

The CEO of Connect Biopharma discusses the unique challenges that patients with asthma and COPD face. Pharmaceutical Executive: What drew you to Connect Biopharma?

COPD has a large economic impact on the healthcare system and a destructive impact on the lives of patients and their ...

Chronic breathlessness, coughing or excess mucus may seem minor, but they could signal chronic obstructive pulmonary disease.

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial.

Australians living with chronic obstructive pulmonary disease (COPD) are being exposed to greater health risks as the use of a critical diagnostic ...

Fatigue is one of the most common symptoms of COPD, so it's important to understand what causes it, columnist Caroline Gainer says.

Yoga can be a valuable complement to pulmonary therapy for chronic respiratory diseases, such as COPD and asthma. By ...